MDS Virtual Congress 2021

September 17-22, 2021. Virtual Congress. www.mdscongress.org

View by Title View Categories

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Obstetrician hands in a pregnant woman

A. Rêgo, P. Neves, S. Machado (Amadora, Portugal)
Obstructive sleep apnea and other vascular risk factors’ impact on Non-motor Symptoms in Parkinson’s Disease

B. Meira, M. Fernandes, M. Salavisa, M. Saraiva, L. Conceiçao, C. Borbinha, F. Ladeira, JP. Marto, R. Barbosa, M. Mendonça, P. Bugalho (Lisbon, Portugal)
Olfactory dysfunction in incidental Lewy body disease and Parkinson’s disease: An update

S. Hasan, C. Adler, N. Zhang, G. Serrano, H. Shill, S. Mehta, T. Beach, E. Driver-Dunckley (Scottsdale, USA)
Oligodendroglial-derived exosomes as mediators of α-synuclein pathology in MSA-like models

M. Vetsi, G. Tsaka, P. Mavroeidi, F. Arvanitaki, M. Zweckstetter, S. Becker, PH. Jensen, L. Stefanis, M. Xilouri (Athens, Greece)
ON/OFF Blood Pressure Fluctuation in Parkinson’s Disease

K. Chung, B. Lobb (Portland, USA)
OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study

G. Bavikatte, G. Francisco, A. Esquenazi, M. Dimyan, K. Ngo, M. Schwartz, A. Zuzek, W. Jost (Liverpool, United Kingdom)
Onset of complications in patients with Parkinson disease in Brazilian Amazon: cohort study.

D. Moura, A. Escudeiro, A. Silva, B. Koshimoto, R. Feio, B. Lobato (Belém, Brazil)
Open-Source Tremor Tracking for MR-guided Focused Ultrasound (MRgFUS): An Objective Approach for Monitoring Treatments

S. Siddiq, A. Mogilner, L. Alon (New York, USA)
Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)
Opicapone in clinical practice in Parkinson’s disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study

H. Reichmann, A. Lees, M. Fonseca, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)
Opicapone in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)
Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study

H. Reichmann, A. Lees, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)
Opicapone in Parkinson’s disease patients with early/simple motor fluctuations: real-world Spanish data

M. Mata Alvarez-Santullano, C. Borrue Fernández, CM. Labandeira Guerra, T. Muñoz Ruiz, J. Abril Jamarillo, V. Gómez Mayordomo, PE. Bermejo Velasco (San Sebastián Reyes, Spain)
OPTI-ON: A Longitudinal Real-World Study of Opicapone in Patients with Parkinson’s Disease and Motor Fluctuations

P. Lewitt, O. Klepitskaya, L. Bahroo, G. Liang, S. Rattana, J. Trotter, M. Serbin (West Bloomfield, USA)
OPTIMIPARK Questionnaire:a tool to optimize treatment in Parkinson´s disease.

J. Máñez-Miró, F. Vivancos-Matellano, L. Vela-Desojo, R. Martinez-Fernandez, F. Alonso-Frech, N. Lopez-Aristegui, E. Balaguer-Martínez, J. Martinez-Castrillo, L. Lopez-Manzanares, P. Martínez-Martín (Madrid, Spain)
Optimizing an Electronic Health Records (EHR)-based Algorithm for Parkinson’s Disease Case Ascertainment

A. Duarte Folle, L. Uhr, F. Agosta, T. Chang, C. Baddley, B. Ritz, C. Tanner, A. Wu, A. Wilson (Los Angeles, USA)
Outcome of Movement Disorders affected by Covid-19: case series from a single Movement Disorders Unit

M. Demirkiran, G. Aktan, M. Balal (Adana, Turkey)
Outcomes of a Peer Reviewing Education and Mentoring Program

D. Garbin Diluca, A. Kirby, C. Goetz (Toronto, Canada)
Outcomes of Gene therapy and Subsequent Deep Brain Stimulation for Parkinson’s Disease

Y. Chintaluru, J. Thomspon, P. David Gerecht, S. Ojemann, D. Kern (Aurora, USA)
Overcoming clinical research challenges during a pandemic: selection and implementation of digital phenotyping solutions in a natural history study of G2019S LRRK2 Parkinson’s disease.

N. France, C. Tomkins-Lane, M. Maurer, C. Barlow, E. Davies, C. Matthews, A. Palozoglu, L. Farid (South San Francisco, USA)
Overview of the population of patients with advanced Parkinson’s disease (aPD) initiating therapy with levodopa-carbidopa intestinal gel (LCIG): POMPE-PARK study on French health insurance data (2013-2017)

JP. Azulay, D. Grabli, S. Benard, N. Kabore, MS. Behier (Marseille, France)

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z